Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes

British Journal of Cancer

Volumn 87, Issue 1, 2002, Pages 106-112

  Marty, C ^a   Odermatt, B ^a   Schott, H ^b   Neri, D ^c   Ballmer Hofer, K ^d   Klemenz, R ^a   Schwendener, Reto A ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ETH ZURICH   (Switzerland)

^d PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

Fibronectin; Immunoliposomes; scFv antibody; Tumour targeting

Indexed keywords

2' DEOXY 5 FLUOROURIDYLYL N4 OCTADECYL 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; CYTARABINE DERIVATIVE; FIBRONECTIN; INDIUM; INDIUM 114M; LIPOSOME; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL COUNT; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TERATOCARCINOMA; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CYTARABINE; FEMALE; FIBRONECTINS; FLUORODEOXYURIDYLATE; IMMUNOGLOBULIN FRAGMENTS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; MICE; MICE, NUDE; TERATOCARCINOMA; TESTICULAR NEOPLASMS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0036649819     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600423     Document Type: Article

References (29)

1. Fibronectin in human prostatic cells in vivo and in vitro: Expression, distribution, and pathological significance
2. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
3. Enhancement of antitumour activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2
4. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain
5. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cyotoxic drug and a p53-independent inducer of apoptosis in the androgen- independent human prostate cancer cell lines PC-3 and DU-145
6. Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes
7. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies
8. Attachment of antibodies to sterically stabilised liposomes: Evaluation, comparison and optimization of coupling procedures
9. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes
10. 4-octadecyl-1-β- D-ara-C
11. Geometric packing constraints in egg phosphatidylcholine vesicles
12. Molecular variants of fibronectin and laminin: Structure, physiological occurrence and histopathological aspects
13. Production of functionalised single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris
14. Immunoliposomes for the targeted delivery of antitumour drugs
15. Source of oncofetal ED-B-containing fibronectin: Implications of production by both tumour and endothelial cells
16. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
17. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumours in mice
18. Anti-HER2 immunoliposomes for targeted therapy of human tumours
19. Structure and function of fibronectin modules
20. Tumour-imaging potential of liposomes loaded with In-111-NTA: Biodistribution in mice
21. Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumour-associated myofibroblasts
22. Roles of macrophages in measles virus infection of genetically modifed mice
23. Fibronectin and its integrin receptors in cancer
24. Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy
25. A high-affinity human antibody that targets tumoural blood vessels
26. Improvement of therapeutic effect by using Fab′ fragment in the treatment of carcinoembryonic antigen-positive human solid tumours with adriamycin-entrapped immunoliposomes
27. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoural angiogenesis
28. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia
29. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon